New pages
Jump to navigation
Jump to search
- 09:51, 27 March 2024 Bismuth subnitrate (hist | edit) [4,643 bytes] Imam Ali Shah (talk | contribs) (Created page with "dasda") Tag: Visual edit
- 08:33, 21 March 2024 Norelgestromin (hist | edit) [40,579 bytes] Alara E. Dagsali (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Alara E.Dagsali |OTC=Yes |genericName=NORELGESTROMIN AND ETHINLY ESTRADIOL patch |indicationType=prevention |indication=Norelgestromin and ethinyl estradiol transdermal system is indicated for the prevention of pregnancy in women with a body mass index (BMI) < 30 kg/m for whom a combined hormonal contraceptive is appropriate. |hasBlackBoxWarning=Yes |adverseReactions=The following serious adverse reactions with the use of co...")
- 23:07, 19 March 2024 Ryzneuta (hist | edit) [10,954 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com]] |genericName=RYZNEUTA -Efbemalenograstim alfa-vuxw |aOrAn=a |drugClass=leukocyte growth factor |indicationType=treatment |indication=and decrease the incidence of infection, as manifested by [febrile neutropenia], in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia |h...")
- 10:01, 12 March 2024 Rezafungin (hist | edit) [4,837 bytes] Hafiza Amna Qadeer (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=HAFIZA AMNA QADEER |OTC=Yes |genericName=REZAFUNGIN |aOrAn=an |drugClass=echinocandin antifungal |indicationType=treatment }}")
- 18:02, 3 March 2024 Non-degenerate nucleotides per response element (hist | edit) [51,688 bytes] Marshallsumter (talk | contribs) (Created page with " {| class="wikitable sortable" |+ Number of non-degenerate nucleotides versus number of response elements |- ! Number of nucleotides !! Letters of nucleotides !! Number of response elements !! Average ± deviation !! Order of list |- | 1 || A || 295 || 295.0 ± 0.0 || 1 |- | 1 || T || 285 || - || 1 |- | 1 || G || 286 || - || 3 |- | 1(4) || C || 300 || 291.5 ± 6 || 5 |- | 2 || AA || 105 || 105 ± 0.0 || 1 |- | 2 || AT || 105 || 105 ± 0.0 || 1 |- | 2 || TA || 74 |...")
- 02:16, 29 February 2024 Lecanemab-irmb (hist | edit) [1,644 bytes] Alen Antony (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{AAP}} |genericName=lecanemab-irmb |aOrAn=a |drugClass=recombinant humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody |indicationType=treatment |indication=Alzheimer’s disease. This drug is ideally initiated during the early phase of dementia or mild cognitive impairment (which was the population tested in the clinical trials of this drug). |hasBlackBoxWarning=Yes |adverseReactions=Amyloid Related Imaging Abnorma...")
- 02:40, 28 February 2024 Vonoprazan fumarate (hist | edit) [23,635 bytes] Kosar Doraghi (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag=Kosar Doraghi, M.D.[mailto:k.doraghi@yahoo.com] |genericName=vonoprazan fumarate |aOrAn=a |drugClass=potassium-competitive acid blocker |indicationType=treatment |indication=all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *to maintain healing of all grades of erosive esophagitis and relief of heartburn associated with erosive esophagitis in adults. *in combinatio...")